Zoledronic Acid Thwarts Cervical Carcinogenesis in Mouse Model

Strategic Insights -

Researchers in the United States have demonstrated that the enzyme inhibitor zoledronic acid can prevent the development of cervical cancer in a mouse model. This breakthrough finding suggests that zoledronic acid may have potential as an 'unconventional' inhibitor for the treatment of cervical cancer and possibly other diseases where matrix metalloproteinase-9 (MMP-9) expression is involved. The study, led by Dr. E. Giraudo, used a mouse model that developed cervical cancers through human papillomavirus type-16 oncogenes, mimicking the stages of cervical cancer in humans.

Key Takeaways:

  • Zoledronic acid, an enzyme inhibitor, prevented the development of cervical cancer in a mouse model.
  • The study used a mouse model that developed cervical cancers through human papillomavirus type-16 oncogenes, mimicking the stages of cervical cancer in humans.
  • The researchers found that zoledronic acid suppressed MMP-9 expression in infiltrating macrophages and inhibited metalloprotease activity, reducing the association of VEGF with its receptor on angiogenic endothelial cells.
  • The study suggests that zoledronic acid may have potential as an 'unconventional' inhibitor for the treatment of cervical cancer and possibly other diseases where MMP-9 expression is involved.
  • The researchers noted that zoledronic acid increased neoplastic epithelial and endothelial cell apoptosis without affecting hyperproliferation, indicating that it was not antimitotic.
  • Zoledronic acid was found to target MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis.

Statistics:

  • The study was published in the Journal of Clinical Investigation (Volume 114, Issue 5, 2004, pages 623-633).
  • The researchers found that the mouse model developed cervical cancers within 3-6 weeks after exposure to human papillomavirus type-16 oncogenes.
  • Zoledronic acid was administered to the mouse model at a dose of 1 mg/kg body weight twice a week for 6 weeks.
  • The study involved the analysis of tumor growth, angiogenesis, and neoplastic cell apoptosis in the mouse model.

Sources:

  • Giraudo et al. (2004). An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest, 114(5), 623-633.
  • University of California San Francisco. Diabetes Center.
  • American Society Clinical Investigation Inc.
  • NewsRx.com & NewsRx.net.